James Anderson, MD, Joins Know Labs as Medical Director

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (OTCQB: KNWN) – the developer of the calorie counter UBAND™ wearable and its underlying non-invasive continuous glucose monitoring technology, announced today that James Anderson, MD, has joined the Company as Medical Director. Dr. Anderson will also serve as Chairman of the Company’s Medical, Scientific and Regulatory Affairs Advisory Board.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180912005360/en/

James Anderson, MD (Photo: Business Wire)

Phil Bosua, Know Labs CEO, stated, “Dr. Anderson immediately understood the science underlying our technology, and shares our vision for its application to medical diagnostics and therapeutics. He brings to us a wealth of relevant experience. Working together we will first focus on blood glucose and a wearable non-invasive continuous glucose monitor.”

James H. Anderson, Jr., M.D., FFPM, FACE, is a diabetologist and endocrinologist who has been in military medicine and the pharmaceutical industry for more than 40 years. A graduate of Centenary College of Louisiana, he earned his M.D. degree from LSU School of Medicine in New Orleans, followed by Internship and Internal Medicine Residency at Charity Hospital in New Orleans. Dr. Anderson began his Fellowship in Endocrinology and Metabolism at LSU, and completed it at the Medical College of Virginia in Richmond.

Summary Excerpts

• Dr. Anderson joined Eli Lilly and Company (LLY) where he was responsible for Lilly’s global clinical diabetes development program. He managed diabetes and cardiometabolic drug clinical development, and drove the clinical development of three families of billion dollar diabetes care products.
• Dr Anderson is a founding editorial board member of two journals for diabetes and serves on the editorial boards or is a reviewer for five other diabetes/endocrine journals. He has also served in local, regional and national positions with the American Diabetes Association.
• Dr. Anderson said, “I am honored and excited to contribute to a unique technology and be a part of a very impressive team. The energy in the lab reflects the creativity and commitment of each of the members, and reminds me of the enjoyment of working with the great teams at Lilly responsible for development of first-of-class pharmaceutical products.”

Following his training he served as Chief of Medicine at the US Army Medical Research Institute for Infectious Diseases, Ft. Detrick, Maryland, where he continued his studies of the effect of infection on diabetes, as well as worked on biological warfare defense, vaccines, and safe care of patients with high hazard infectious diseases. He also served as the safety physician for the very first Level 3 recombinant DNA experiments performed by the US NIH. Lt. Col. Anderson then moved to Brooke Army Medical Center at Ft. Sam Houston, San Antonio, Texas, where he served as Chairman of the Department of Clinical Investigation and Consultant to the Surgeon General of the Army for Clinical Investigation. During that time, he acquired the Army’s first artificial pancreas to aid in the investigation of immune factors in the etiology of diabetes. While in San Antonio, he also was an independent investigator for Lilly’s development of rDNA human insulin for therapeutic use.

Dr. Anderson then joined Eli Lilly and Company (LLY), where he was responsible for Lilly’s global clinical diabetes development program. He managed diabetes and cardiometabolic drug development, and drove the clinical development, registration and launch of two families of billion dollar diabetes care products, Humulin® (human insulin of rDNA origin) and Humalog®, the first rapid acting analog of human insulin. He led the clinical development and was responsible for six US NDAs, and had clinical responsibility for insulin products worldwide. He also evaluated and/or conducted the initial clinical development of human insulin and insulin analog pre-mixtures, basal insulin analogs, pulmonary and oral insulin, as well as small molecule, oral drugs for type 2 diabetes. Dr. Anderson re-focused the strategic clinical direction for marketed products and investigational drugs, the conduct of global clinical trials and the clinical development of numerous compounds in Phase I- Phase IV. He held pivotal roles directing Lilly’s endocrine products in Japan, global medical-marketing, internal discovery, and in-licensing opportunities. He was the first in the industry to envision and accomplish a strategic concurrent global clinical development and registration program, which secured a first to market position for Lilly’s Humalog. Prior to retiring from Lilly, Dr. Anderson led the initial development of Lilly’s drug for diabetes – dulaglutide [Trulicity™] which is Lilly’s third billion-dollar diabetes drug.

A strong believer in education, Dr. Anderson has served on the medical faculties of LSU School of Medicine, Medical College of Virginia, Uniformed Services University of the Health Sciences, the University of Texas Health Science Center San Antonio, and Indiana University School of Medicine, where he is currently a Clinical Associate Professor of Medicine for the Division of Endocrinology and Metabolism.

Internationally recognized, Dr. Anderson is an elected Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK and was a founding board member of the American Association of Pharmaceutical Physicians. He is also a Fellow of the American College of Endocrinology. He is a founding editorial board member of two journals for diabetes and serves on the editorial boards or is a reviewer for five other diabetes/endocrine journals. He has also served in local, regional and national positions with the American Diabetes Association.

In addition to serving as Medical Director for PTS Diagnostics, he currently holds positions as CEO of Diabetes and CardioMetabolic Disease Solutions Group, a Medical Director for Catapult Health and CEO of Mitozyme. Dr. Anderson has served as Senior Scientific Advisor and is currently a member of the Board of Directors for Generex Biotechnology Corporation (GNBT).

Upon joining the Know Labs team Dr. Anderson said, “I am honored and excited to contribute to a unique technology and be a part of a very impressive team. The energy in the lab reflects the creativity and commitment of each of the members, and reminds me of the enjoyment of working with the great teams at Lilly responsible for development of first-of-class pharmaceutical products. Working together we plan to bring the first truly non-invasive continuous glucose monitor to the market. It is our shared goal to make a significant difference in the lives of all of those affected by diabetes.”

Know Labs Founder and Chairman Ron Erickson added, “Dr. Anderson is a wonderful addition to the Know Labs team. He brings a wealth of experience to our focused efforts to develop a non-invasive continuous glucose monitor. With his guidance we can pursue other significant applications for our non-invasive diagnostic technology. We are thrilled to work with him.”

About Know Labs, Inc.

Know Labs, Inc. (f/k/a Visualant Incorporated) is a public company whose shares currently trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. UBAND™, ChromaID™ and Bio-RFID™ are trademarks of Know Labs, Inc. For more information on Know Labs, visit the company’s website at www.knowlabs.co.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180912005360/en/